Chong Kun Dang Pharmaceutical Corp.
š°š·South Korea
- Country
- š°š·South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers
Phase 1
Active, not recruiting
- Conditions
- Dyslipidemia
- Interventions
- Drug: D352Drug: D794
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 36
- Registration Number
- NCT06758661
- Locations
- š°š·
H Plus Yangji Hospital, Gwanak-gu, Seoul, Korea, Republic of
A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants
Phase 1
Recruiting
- Conditions
- Healthy Subjects
- Interventions
- Drug: CKD-508 TabletDrug: Placebo Tablet
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 40
- Registration Number
- NCT06727396
- Locations
- šŗšø
Research Site, Glendale, California, United States
Clinical Study to Evaluate the Food Effect of CKD-378 in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Drug: CKD-378 25/1000mg
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT06709807
- Locations
- š°š·
H Plus Yangji Hospital, Gwanak-gu, Seoul, Korea, Republic of
Clinical Study to Evaluate the Food Effect of CKD-383 0.5/10/1000mg in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Drug: CKD-383
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT06695572
- Locations
- š°š·
Bumin Hospital, Gangseo-gu, Seoul, Korea, Republic of
Clinical Study to Evaluate the Food Effect of CKD-383 0.5/25/1000mg in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Drug: CKD-383
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT06695598
- Locations
- š°š·
Bumin Hospital, Gangseo-gu, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Food Effect of CKD-379
Phase 1
Completed
- Conditions
- Type II Diabetes Mellitus
- Interventions
- Drug: CKD-379
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT06652971
- Locations
- š°š·
Bumin Hospital, Gangseo-gu, Seoul, Korea, Republic of
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Phase 3
Not yet recruiting
- Conditions
- Essential Hypertension
- Interventions
- Drug: sacubitril/valsatran(dose maintenance)Drug: sacubitril/valsartan(dose increasing)Drug: Valsartan
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 324
- Registration Number
- NCT06643819
- Locations
- š°š·
Wonju Severance Christian Hospital, Wonju, Korea, Republic of
To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers
Phase 1
Not yet recruiting
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: CKD-383(Fed)Drug: CKD-383(Fasted)
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT06492655
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 45
- Registration Number
- NCT06483243
- Locations
- š°š·
Chung-Ang University Gwangmyeong Hospital, Gyeonggi-do, Korea, Republic of
Efficacy and Safety of Telmisartan Compared With Losartan
Phase 4
Recruiting
- Conditions
- Diabetic NephropathiesHypertension
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 98
- Registration Number
- NCT06431477
- Locations
- š°š·
Severance Hospital, Seoul, Korea, Republic of
Ā© Copyright 2025. All Rights Reserved by MedPath